Adverum Biotechnologies, Inc. (ADVM)
$
2.26
+0.05 (2.21%)
Key metrics
Financial statements
Free cash flow per share
-5.3733
Market cap
46.2 Million
Price to sales ratio
-17.7571
Debt to equity
3.5265
Current ratio
3.5654
Income quality
0.7312
Average inventory
0
ROE
-1.2267
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops innovative gene therapy product candidates aimed at treating ocular and rare diseases. The company's lead product candidate, ADVM-022, represents a significant advancement as a single intravitreal injection gene therapy designed for patients suffering from chronic retinal conditions, including wet age-related macular degeneration and diabetic macular edema. The company reported selling, general, and administrative expenses of $63,118,000.00 indicating its operational overhead costs. Additionally, the earnings per share (EPS) is reported at -$6.62 which reflects the company's profitability on a per-share basis, while the diluted EPS stands at -$6.62 accounting for potential share dilution. The operating income ratio is -139.16 demonstrating the company's operational profitability margin, and the weighted average number of shares outstanding is 19,782,000.00 highlighting the company's shareholder base. Established in 2006 and previously known as Avalanche Biotechnologies, Inc., the company rebranded as Adverum Biotechnologies, Inc. in May 2016. It has also formed strategic license and collaboration agreements with prestigious institutions such as the University of California, Cornell University, and companies like GenSight, Lexeo, and Virovek. With a market capitalization of $47,212,982.00 the company is classified as a small-cap player and operates within the Biotechnology industry, contributing significantly to the overall market landscape. The stock is affordable at $2.26 making it suitable for budget-conscious investors. However, it is worth noting that the stock has a low average trading volume of 327,514.00 indicating lower market activity. Adverum Biotechnologies, Inc. holds a crucial position in the Healthcare sector, driving innovation and growth, and it continues to be a key player in the evolving field of gene therapy, aiming to make a lasting impact on the treatment of ocular and rare diseases.
Is Adverum Biotechnologies, Inc. (ADVM) a good investment?
Investing in Adverum Biotechnologies, Inc. (ADVM) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is Adverum Biotechnologies, Inc. (ADVM)'s stock forecast?
Analysts predict Adverum Biotechnologies, Inc. stock to fluctuate between $1.78 (low) and $10.14 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Adverum Biotechnologies, Inc.'s market capitalization?
As of 2025-05-29, Adverum Biotechnologies, Inc.'s market cap is $47,212,982, based on 20,890,700 outstanding shares.
How does Adverum Biotechnologies, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Adverum Biotechnologies, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Adverum Biotechnologies, Inc. (ADVM) stock?
To buy Adverum Biotechnologies, Inc. (ADVM) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ADVM. Place an order (Market, Limit, etc.).
What is the best time to invest in Adverum Biotechnologies, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Adverum Biotechnologies, Inc. stock ever split?
Adverum Biotechnologies, Inc.'s last stock split was 1:10 on 2024-03-21.
How did Adverum Biotechnologies, Inc. perform in the last earnings report?
Revenue: $1,000,000 | EPS: -$6.62 | Growth: -45.33%.
Where can I find Adverum Biotechnologies, Inc.'s investor relations reports?
Visit https://www.adverum.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Adverum Biotechnologies, Inc.?
You can explore historical data from here
What is the all-time high and low for Adverum Biotechnologies, Inc. stock?
All-time high: $146 (2021-02-10) | All-time low: $1.78 (2025-05-15).
What are the key trends affecting Adverum Biotechnologies, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. ("Adverum" or "the Company") (NASDAQ:ADVM). Investors who purchased Adverum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADVM.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / April 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / April 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
See all news
